## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.9% below STRENGTH zone (4.0-10.0%); PEG 1.89 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($189.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Natixis Cuts Stock Position in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251209T130811 | Somewhat-Bullish | Relevance: 100%
-  Natixis reduced its stake in Cardinal Health, Inc. (NYSE:CAH) by 45.8% in the second quarter, selling 72,854 shares but still owning 86,051 shares valued at $14.46 million. Despite this, Cardinal Health reported strong Q2 earnings, beating analyst estimates with $2.55 EPS and setting positive FY2026 guidance, leading to a consensus "Moderate Buy" rating from analysts. Other institutional investors, however, increased their positions in the company, highlighting mixed sentiment among institutional holders.

**2. California Public Employees Retirement System Sells 156,287 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251208T095735 | Somewhat-Bullish | Relevance: 98%
- California Public Employees Retirement System reduced its stake in Cardinal Health by 14.1%, selling 156,287 shares, though it still holds 953,908 shares valued at $160.3 million. Despite this sale, institutional ownership remains high at 87.17% due to significant new investments from other large institutions like Norges Bank and JPMorgan. Analysts rate Cardinal Health as a "Moderate Buy" with an average target price of $206.57, following strong quarterly earnings and positive FY2026 EPS guidance.

**3. Amundi Sells 1,183,078 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251208T081427 | Somewhat-Bullish | Relevance: 98%
-  Amundi significantly reduced its stake in Cardinal Health, Inc. (NYSE:CAH) by selling 1,183,078 shares in the second quarter, decreasing its holding by 62.2%. Despite this, other institutional investors like Marshall Wace LLP and GeoWealth Management LLC increased their positions. Cardinal Health (CAH) has a "Moderate Buy" consensus rating from analysts, recently beat Q3 earnings estimates, and maintains a $2.04 annual dividend.

**4. Axa S.A. Sells 84,695 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251209T083059 | Bullish | Relevance: 98%
-  Axa S.A. has reduced its stake in Cardinal Health, Inc. (NYSE:CAH) by 15.2% during the 2nd quarter, selling 84,695 shares and now holding 472,833 shares valued at approximately $79.44 million. Despite this, Cardinal Health reported strong quarterly earnings, beating expectations with an EPS of $2.55 and revenue of $64.01 billion, and set a positive FY2026 guidance. Institutional ownership remains high at 87.17%, with several analysts raising price targets and a consensus "Moderate Buy" rating.

**5. CW Advisors LLC Grows Stake in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251207T092158 | Bullish | Relevance: 98%
- CW Advisors LLC significantly increased its stake in Cardinal Health, Inc. (NYSE:CAH) by 130.6% in Q2, boosting its holdings to 18,656 shares valued at approximately $3.13 million. This increase comes alongside strong financial performance from Cardinal Health, which exceeded Q2 earnings expectations with an EPS of $2.55 and revenue of $64.01 billion, leading to a positive outlook with mostly "Buy" ratings from analysts and a consensus price target of $206.57. The company also declared a quarterly dividend of $0.5107.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.89 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $47.0B |
| Beta | 0.64 |
| 52W Range | $114.60 - $214.93 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.89 |
| Forward P/E | 17.9 |
| Current P/E | 20.1 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.9% over 5 days). Below STRENGTH zone by 9.9pp (needs >4.0% for momentum thesis). AM_20 at -3.8% indicates price below own 20MA trend. Long-term uptrend intact (above SMA200 at 1.26x) but short-term weakness (below SMA20). MACD histogram bearish (-3.09), momentum weakening. RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.90% (CS: 12) | Weak |
| RSI_14 | 49.9 | Neutral |
| MACD Histogram | -3.09 | Bearish |
| vs SMA20 | 0.962x | Below |
| vs SMA50 | 1.081x | Above |
| vs SMA200 | 1.264x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $198.00
- **Stop Loss:** $189.66 (4.2% risk)
- **Target:** $206.34 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 35
- **Position Value:** $6,930.00
- **Portfolio %:** 6.93%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*